Would you ever consider using durvalumab/tremelimumab in second line after progression on atezolizumab and bevacizumab in advanced HCC?

This is a really interesting question as primary prospective trials in this setting are limited. Following progression of atezolizumab/bevacizumab, there was a recent abstract of a phase 2 trial using the combination regorafenib + pembrolizumab (N=95 patients, cohort 1 of 68 patients having received...

I would consider using durvalumab/tremelimumab in second line after progression on Atezolizumab and Bevacizumab in advanced HCC.

If not previously used, both Category 1, NCCN accepted first-line HCC regimens: atezolizumab plus bevacizumab and trelimumab plus durvalumab are reasonable to consider for subsequent lines of treatment. However, there is no comparative data to define optimal treatment after first-line systemic thera...